XORTX Therapeutics Finalizes 1:5 Reverse Stock Split to Meet NASDAQ Listing Requirements

summarizeSummary

XORTX Therapeutics announced the board's approval and effective date for a 1-for-5 reverse stock split, a crucial step to meet NASDAQ's minimum bid price requirement and avoid delisting.

check_boxKey Events

• Board Approves 1:5 Reverse Stock Split

  The board of directors has approved a 1-for-5 reverse stock split, reducing outstanding shares from approximately 6.96 million to 1.39 million.

• NASDAQ Compliance Critical

  The consolidation is necessary to meet NASDAQ's minimum $1.00 bid price requirement and a specific condition to trade above $1.00 for 10 days by April 13, 2026.

• Effective Date Set

  The reverse stock split is effective March 27, 2025 (likely a typo, should be 2026), with post-consolidation trading expected to begin on or about March 27, 2026.

• Follows Shareholder Approval

  This action follows shareholder approval for a consolidation of up to 5:1 at the annual meeting on March 24, 2026.

auto_awesomeAnalysis

This filing confirms the board's approval and effective date for the previously announced 1-for-5 reverse stock split. This action is critical for XORTX Therapeutics to regain compliance with NASDAQ's minimum bid price requirement, especially given the company's current stock price trading near 52-week lows and the recent "going concern" warning disclosed in its 20-F filing on March 20, 2026. While a reverse split is often viewed negatively as it doesn't address underlying business issues, it is a necessary step to maintain the company's listing and access to capital markets. Investors should monitor the stock's performance post-split to see if it can sustain the $1.00 minimum bid price.